Antioxidative and anti-inflammatory effects of metformin; a new look to an old drug

Amin Hasanvand*

The result of decreased antioxidant defense system and also, increased pro-inflammatory cytokines are detectable in chronic diseases such as diabetes (neuropathy and nephropathy), cardiovascular disorders (hypertension), metabolic syndrome, hepatotoxicity, ototoxicity and infectious disorders. An excess of reactive oxygen species (ROS) cause cellular degradation process that leads to cell damage and induced apoptosis (1-3). Reduction of the ROS with drug treatment and/or diet variation strategy would give a nice objective for suppression of ischemia-reperfusion (I/R) damage in the kidney (4). Recent studies suggest that in the intestinal mucosa of patients with irritable bowel syndrome (IBS), immune cells were activated, and suggest a possible role for low-grade inflammation in the pathogenesis of IBS. Evidence suggests that ROS, pro-inflammatory cytokines and damaged tissue caused hypersensitivity of visceral vessels which is thought to play a main role in the increase of chronic pain and distress in IBS (5).

For most conditions, these diseases can be managed with an appropriate preventive and treatment methods and training for patients. Metformin, a biguanide drug, is broadly prescribed to treat high blood glucose in patients with type 2 diabetes mellitus. This drug improves infarct size and reduces adverse restoration in animals with diabetic or nondiabetic and delays the development of heart failure in nondiabetic animals. In addition to its effect on heart failure, administration of metformin has beneficial effects of diminishing endotoxemia and improves insulin signaling pathway in animals. There is the positive effect of metformin on decreasing oxidative stress activity in the body (6). Acetaminophen (acetyl-para-aminophenol [APAP]) poisoning can cause necrosis of the centriflobular cells, fatty degeneration and increased inflammation. In addition, acetaminophen-induced hepatotoxicity is believed to be mediated by increasing pro-inflammatory cytokines (such as IL-6, TNF-a and CRP levels), tissue enzymes (such as AST, ALT, ALP and malondialdehyde), and also through decreasing glutathione and superoxide dismutase activities. Our recent study suggests, a 21-day treatment with metformin (200 mg/kg/d) protects hepatocytes against acute APAP hepatotoxicity. ROS and pro-inflammatory cytokines play a main effect in toxicity of APAP, resulting in acute hepatotoxicity. However, improved hepatocyte necrosis, attenuated antioxidant defense system, diminish proinflammatory cytokines and prevention of tissue damage were also found with metformin treatment (7). Recent investigations have shown that metformin may have a role to improve nephropathy of diabetes (8). Also, studies have suggested that metformin treatment improved gentamicin-induced renal toxicity in Wistar rats (9). In this study, it has been shown that administration of metformin after the development of tubular damage by gentamicin, can ameliorate tissue injury. Likewise, co-administration of garlic extract and metformin has a role in protection against oxidative stress in renal toxicity (10). The main target of metformin is mitochondrial respiratory chain complex I, which can result in the activation of the adenosine monophosphate-activated protein kinase (AMPK) signaling pathway (11). In general, the stimulation of AMPK signaling pathway with metformin causes antioxidant and anti-inflammation effects. And finally, It has been suggested the attenuation of chronic diseases.

Author's contribution
AH is the single author of the manuscript.

Conflicts of interest
The author declared no competing interests.

Ethical considerations
Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by the author.

Funding/Support
None.

References

*Corresponding Author: Amin Hasanvand, Email: dr.hasanvand@yahoo.com


**Citation:** Hasanvand A. Antioxidative and anti-inflammatory effects of metformin; a new look to an old drug. J Renal Endocrinol. 2017;4:e2. **Copyright © 2018 The Author(s); Published by Nickan Research Institute. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.**